The long history of HER2 testing in breast cancer is an indication of the importance of continuing efforts to improve HER2 diagnostic assays and their interpretation, to ensure that patients who may benefit receive the appropriate targeted therapy. Here, ERBB2 is linked to breast carcinoma.